Forest Laboratories, Inc. (FRX) announced that the U.S. Food and Drug Administration's or FDA Anti-Infective Drugs Advisory Committee voted 21 - 0 in favor of approval of ceftaroline fosamil.
Ceftaroline Fosamil was approved for the treatment of community acquired bacterial pneumonia or CABP and voted 18 - 0 in favor of approval for complicated skin and skin structure infections or cSSSI, the company noted.
Commenting about Ceftaroline, the company said it is a novel, bactericidal, broad-spectrum injectable cephalosporin shown in pre-clinical and clinical trials to have activity against both gram-positive pathogens, including methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae, and common gram-negative pathogens.
For comments and feedback: editorial@rttnews.com